MXCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MXCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. MaxCyte's average diluted shares outstanding for the quarter that ended in Mar. 2024 was 104.09 Mil.
The historical data trend for MaxCyte's Shares Outstanding (Diluted Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shares Outstanding (Diluted Average) | Get a 7-Day Free Trial | 56.40 | 69.47 | 90.62 | 101.70 | 103.27 |
MaxCyte Quarterly Data | ||||||||||||||||||||
Jun18 | Dec18 | Jun19 | Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shares Outstanding (Diluted Average) | Get a 7-Day Free Trial | 102.85 | 103.06 | 103.45 | 103.71 | 104.09 |
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
MaxCyte (NAS:MXCT) Shares Outstanding (Diluted Average) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Thank you for viewing the detailed overview of MaxCyte's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.
John Joseph Johnston | director | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Douglas Doerfler | director, officer: President and CEO | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Thomas M. Ross | officer: EVP, Global Sales | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Richard Douglas | director | ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
Douglas J Swirsky | officer: Chief Financial Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850 |
Patrick J Balthrop | director | C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850 |
Casdin Partners Master Fund, L.p. | 10 percent owner | WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001 |
Cenk Sumen | officer: Chief Scientific Officer | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Amanda Louise Murphy | officer: Chief Financial Officer | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Maher Masoud | officer: EVP and General Counsel | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Ron Holtz | officer: SVP and CAO | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Yasir B. Al-wakeel | director | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Art Mandell | director | C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
William W Brooke | director | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
Thompson J Stark Phd | director |
From GuruFocus
By Marketwired • 10-04-2023
By Marketwired • 09-06-2023
By sperokesalga sperokesalga • 04-12-2023
By GuruFocusNews GuruFocusNews • 05-13-2022
By GuruFocusNews GuruFocusNews • 04-20-2022
By GuruFocusNews GuruFocusNews • 06-02-2022
By GuruFocusNews GuruFocusNews • 05-03-2022
By GuruFocusNews GuruFocusNews • 04-15-2022
By Marketwired • 08-01-2023
By sperokesalga sperokesalga • 06-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.